Skip to content

Search

The Kids Research Institute Australia Director elected to prestigious Australian Academy of Science

Prof Jonathan Carapetis has been elected as a new Fellow of the prestigious Australian Academy of Science in recognition of his pioneering, paradigm-shifting expertise in infectious diseases.

Preventing RHD through community-driven activities

Health activities driven by remote Indigenous communities may be key to the sustainable and successful treatment and prevention of a potentially fatal disease, a study has found.

New RHD research collaboration with Danila Dilba Health Service

The Kids Research Institute Australia and Menzies School of Health Research have joined forces with Danila Dilba Health Service to look at improving treatment for RHD.

RHD Endgame Strategy

The END RHD CRE focuses priority research projects that will help achieve the singular target of producing the Endgame Strategy.

Meet END RHD CRE Researcher Dr Simone Reynolds

Learn more about the background and motivations of END RHD CRE Research Fellow Simone Reynolds.

Carol's story: losing a parent to RHD

After being diagnosed with rheumatic heart disease at ten, Elizabeth had to leave country and her family for a large chunk of her childhood so she could be treated in Adelaide.

Margie's story: Parent to a child with ARF

When Liana complained of a sore foot and showed signs of a fever, her mum Margie rushed her to hospital. An X-ray of her foot revealed no obvious injury, so she was sent home and advised to take painkillers.

2017 Annual Meeting – Darwin

On 11 May 2017, over 60 attendees from throughout Australia convened in Darwin for a one-day Annual Meeting to discuss the progress of the END RHD CRE research projects, national RHD advocacy and the development of the final Endgame output.

The Kids Research Institute Australia researchers awarded $11 million to support vital child health research

Researchers from The Kids Research Institute Australia have been awarded more than $11 million to support vital child health projects, under the Federal Government’s Medical Research Future Fund.

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.